Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 336 | 47% |
| 2020 | 2 | 283 | 50% |
| 2021 | 2 | 260 | 53% |
| 2022 | 1 | 278 | 56% |
| 2023 | 3 | 299 | 58% |
| 2024 | 7 | 370 | 60% |
| 2025 from claims | – | 826 668–970 | 61% |
| 2026 forecast | – | 919 720–1,155 | 61% |
| 2027 forecast | – | 999 741–1,321 | 61% |
| 2028 forecast | – | 1,086 769–1,498 | 61% |
| 2029 forecast | – | 1,179 802–1,691 | 62% |
| 2030 forecast | – | 1,281 839–1,901 | 62% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Ohio; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 31% hospital outpatient, 67% office. The share outside the hospital has moved +67 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~920 | ~22 | ~220 | ~670 |
| 2027 · ~1,000 | ~23 | ~210 | ~760 |
| 2028 · ~1,100 | ~24 | ~210 | ~850 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 78% (67% in 2025), hospital outpatient about 19% (31% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 14 | 674+3.6%/yr | +3.6%/yr | 0.5 | 49% | 1,750 in 2030+17%/yr |
| Michigan | 7 | 565+12%/yr | +12%/yr | 0.7 | 78% | 1,300 in 2030+15%/yr |
| Missouri | 6 | 541+7.4%/yr | +7.4%/yr | 0.9 | 56% | 860 in 2030+8.1%/yr |
| Wisconsin | 4 | 296+1.8%/yr | +1.8%/yr | 0.5 | 0% | 330 in 2030+1.9%/yr |
| Indiana | 5 | 282+1.3%/yr | +1.3%/yr | 0.4 | 61% | 580 in 2030+13%/yr |
| Minnesota | 4 | 239+0.6%/yr | +0.6%/yr | 0.5 | 45% | 380 in 2030+7.9%/yr |
| Iowa | 3 | 178+14%/yr | +14%/yr | 0.4 | 0% | 260 in 2030+6.8%/yr |
| Kansas | 3 | 164+3.8%/yr | +3.8%/yr | 0.4 | 65% | 580 in 2030+24%/yr |
| Nebraska | 2 | 116+16%/yr | +16%/yr | 0.4 | 23% | 210 in 2030+10%/yr |
| South Dakota | 2 | 101+20%/yr | +20%/yr | 0.8 | 42% | 180 in 2030+9.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 133 | 7,179−2.5%/yr | −2.5%/yr | 7.01.0× | 2% | 6,960 in 2030−0.5%/yr |
| Tumor ablation | 1 | 253−4.9%/yr | −4.9%/yr | 0.20.7× | 0% | 520 in 2030+13%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
Exact Sciences leads with 37% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 18 companies reported engagement with Ohio’s surgeons worth $371K in consulting, speaking, meals and travel tied to these products, about $53K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.